Komipharm International Co (041960) Fair Value & Analysis

Healthcare · KR · Market cap 617B KRW

Analysis

Komipharm International Co (041960) currently trades at 8,120 KRW, while our model-based Fair Value estimate is 949.94 KRW — implying the stock looks roughly 88.3% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Komipharm International Co., Ltd. manufactures and sells veterinary vaccines, veterinary pharmaceuticals and disinfectants, and bio-fertilizers internationally. It also develops anticancer drugs and pain-relieving agents, which include Kominox, an arsenic-based oral drug; and Panaphix, a non-narcotic cancer pain reliever, as well as provides clinical pathological experiment, test, and analysis services. The company was formerly known as Korea Microbiological Laboratories Co., Ltd. and changed its name to Komipharm International Co., Ltd. in September 2004. The company was founded in 1972 and is headquartered in Siheung, South Korea.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.